Hanmi's Amosartan receives MAs in three CIS countries

Hanmi Pharmaceutical has obtained marketing authorisations for Amosartan in three Commonwealth of Independent States countries including Kazakhstan, Uzbekistan, and Turkmenistan. Amosartan is an amlodipine+losartan fixed-dose combination drug, used in the treatment of hypertension. Hanmi has agreed for Merck Sharp & Dohme to market and supply the combination drug to over 51 countries, branded as Cozaar XQ. The MAs obtained for the CIS countries were in addition to the 51 countries marketed via MSD; Hanmi added that such procedures are ongoing for Amosartan's regulatory approval in more than ten other countries.


Enter your details to read the full article

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.